Loading
Life sciences · Journal article
Pediatric Hematology Oncology Journal · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chemotherapy dosing in children usually begins with body size, but body size alone does not reliably predict drug exposure or toxicity across pediatric development. This review synthesizes current evidence to guide dosing approaches in pediatric oncology. Well-established approaches to optimizing cancer drug therapy include adjusting thiopurine doses based on TPMT and NUDT15 genetic profiles; using target drug exposure levels to guide Busulfan and carboplatin dosing; monitoring high-dose Methotrexate concentrations and administering leucovorin rescue; and measuring asparaginase activity levels in specific treatment protocols. In contrast to fixed-dose regimens, maintenance therapy for acute lymphoblastic leukemia uses a dynamic approach in which treatment intensity is titrated according to each patient's hematologic tolerance. Three dosing concepts, including dose modification, prospective dose individualization, and dose optimization during drug development, are frequently used interchangeably, but they represent distinct approaches that must be distinguished carefully. Machine-learning prediction tools, point-of-care pharmacokinetic systems, and closed-loop dosing remain in their early stages.